Clinical trial
Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study
NCT02693158 is registered in ClinicalTrials.gov with Svelte Medical Systems, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study
- Lead sponsor
- Svelte Medical Systems, Inc.
- Phase
- Observational
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- January 31, 2020
- Enrollment
- 440 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.